FDA approves new treatment for rare form of thyroid cancer
Wed, 06 Apr 2011 14:57:00 -0500
The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.
Manage your FDA Subscriptions:
- Update your preferences or unsubscribe
- Questions about this service? support@govdelivery.com
- Other inquiries? webmail@oc.fda.gov
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420
No comments:
Post a Comment